Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

UK National Cancer Imaging Translational Accelerator (NCITA) establishes infrastructure for validation and adoption of cancer imaging biomarkers as decision-making tools in clinical trials and NHS practice. Researchers and medical experts from nine world-leading medical imaging centres across the UK come together to form an integrated infrastructure for standardising and validating cancer imaging biomarkers for clinical use.

None

The centres include University of Oxford, University College London, University of Manchester, King’s College London, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, Imperial College London, Cambridge University, Newcastle University and University of Glasgow.  This unique UK infrastructure provides clinical researchers across the UK with open access to world-class clinical imaging facilities and expertise, as well as a repository data management service, artificial intelligence (AI) tools and ongoing training opportunities.

The NCITA consortium, through engagement with NHS Trusts, pharmaceutical companies, medical imaging and nuclear medicine companies as well as funding bodies and patient groups, aims to develop a robust and sustainable imaging biomarker certification process, to revolutionise the speed and accuracy of cancer diagnosis, tumour classification and patient response to treatment. 

Read the full story on the Department of Oncology website

Similar stories

EAVI2020: The Quest for an HIV Vaccine

In this long read published to coincide with International AIDS Day, we explore how an international collaboration – of which the University of Oxford is a key partner – has boosted HIV vaccine research. We thank our partners at Imperial College London for allowing us to reproduce and abridge this article.

New SMRU building opened in Thailand to provide health care to marginalized populations

The inauguration of a new joint Shoklo Malaria Research Unit (SMRU) and Borderland Health Foundation (BHF) Building took place in Mae Ramat, Thailand, this week.

Smoking increases the risks of 56 diseases in Chinese adults

Smoking increases the risks of 56 diseases and kills more than one million adults in China each year from 22 different causes, according to new research published in The Lancet Public Health.

Success for Oxford researchers in The Genetics Society 2023 Awards

Researchers from Department of Physiology, Anatomy and Genetics, Radcliffe Department of Medicine and Nuffield Department of Population Health have been recgonised in The Genetics Society 2023 awards.

New Studentship honours Enzo Cerundolo

A new Studentship has been announced in memory of the late MRC HIU Director and MRC WIMM Group Leader.